Feedback
Pain Management Panel, Screen with Reflex to Quantitation
2012312
Ordering Recommendation

Use for general testing in contexts of compliance and/or abuse, primarily in the pain management population. Alternative testing strategies include Pain Management Drug Panel by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2007479) and Pain Management Drug Panel with Interpretation by High-Resolution Time-of-Flight or Tandem Mass Spectrometry and Enzyme Immunoassay, Urine (2009288).

Mnemonic
PAIN RFX U
Methodology
Qualitative Enzyme Immunoassay/Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Sun-Sat
Reported
1-8 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
ARUP Consult®
Disease Topics
Specimen Required
Patient Preparation
 
Collect
Random Urine. 
Specimen Preparation
Transfer 4 mL each into two (2) ARUP Standard Transport Tubes urine with no additives or preservatives. (Min: 2 mL each) 
Storage/Transport Temperature
Refrigerated. 
Unacceptable Conditions
Specimens exposed to multiple freeze/thaw cycles, Pharmaceutical preparation. 
Remarks
 
Stability
Ambient: 1 week; Refrigerated: 1 month; frozen: 3 years 
Reference Interval
Drugs covered and range of cutoff concentrations
Drugs/Drug ClassesScreen
Amphetamines300 ng/mL
Barbiturates200 ng/mL
Benzodiazepines200 ng/mL
Buprenorphine5 ng/mL
Carisoprodol100 ng/mL
Cocaine150 ng/mL
Ethyl Glucuronide500 ng/mL
Fentanyl2 ng/mL
MDMA (Ecstasy)500 ng/mL
Meperidine200 ng/mL
Methadone150 ng/mL
Opiates300 ng/mL
Oxycodone100 ng/mL
Phencyclidine25 ng/mL
Propoxyphene300 ng/mL
Tapentadol200 ng/mL
Tramadol200 ng/mL
THC (Cannabinoids)20 ng/mL
Zolpidem20 ng/mL

Interpretive Data
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration at which the screening test can detect a drug or metabolite varies. Specimens for which drugs or drug classes are detected by the screen are reflexed to a second, more specific technology (GC/MS and or LC MS/MS). The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.

For medical purposes only; not valid for forensic use.

Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.

Note
If the specimen screens positive then Confirmation/Quantitation by LC-MS/MS will be added to confirm result. Additional charges apply.
CPT Code(s)
80307; if positive add appropriate CPT: 80324; 80359; 80345; 80346; 80348; 80369; 80353; 80321; 80354; 80362; 80358; 80349; 80361; 80365; 83992; 80367; 80368; 80372; 80373 (Alt code: if positive, add appropriate CPT code(s): G0480)
Components
Component Test Code*Component Chart NameLOINC
0090386Creatinine, Urine2161-8
0092191Amphetamines, Urn, Screen19348-2
0092192Cocaine, Urn, Screen19359-9
0092194Phencyclidine, Urn, Screen19661-8
0092195THC, Urn, Screen19292-2
0092196Barbiturates, Urn, Screen19276-5
0092197Benzodiazepines, Urn, Screen19284-9
0092198Propoxyphene, Urn, Screen19432-4
0092199Methadone, Urn, Screen19553-7
2005094Opiates, Urn, Screen19295-5
2005102Oxycodone/Oxymorphone, Urn, Screen
2007913Ethyl Glucuronide Screen w/Rflx, Urine58375-7
2012212Screen, Urine Interpretation54247-2
2012274Buprenorphine, Urn, Screen3415-7
2012279Carisoprodol, Urn, Screen10979-3
2012285Fentanyl, Urn, Screen11235-9
2012289Meperidine, Urn, Screen19534-7
2012295Tapentadol, Urn, Screen65807-0
2012298Tramadol, Urn, Screen19712-9
2012301Zolpidem, Urn, Screen33339-3
* Component test codes cannot be used to order tests. The information provided here is not sufficient for interface builds; for a complete test mix, please click the sidebar link to access the Interface Map.
Aliases
  • See individual components